{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:43Z","timestamp":1761498523461,"version":"build-2065373602"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.beha.2019.101139","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T12:45:59Z","timestamp":1577364359000},"page":"101139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myelodysplastic\/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?"],"prefix":"10.1016","volume":"33","author":[{"given":"V.F.I.","family":"Sangiorgio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2019.101139_bib1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"year":"2017","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","key":"10.1016\/j.beha.2019.101139_bib2"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.beha.2019.101139_bib4","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2010-07-295857","article-title":"Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies","volume":"117","author":"Tiu","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2019.101139_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.beha.2019.101139_bib6","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.beha.2019.101139_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2019.101139_bib8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.101139_bib9","series-title":"World Health organization classification of tumors: Pathology and genetics of tumours of haematopoietic and lymphoid tissues","first-page":"47","article-title":"Myelodysplastic\/myeloproliferative diseases: introduction","author":"Vardiman","year":"2001"},{"year":"2008","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","key":"10.1016\/j.beha.2019.101139_bib10"},{"issue":"5\u20136","key":"10.1016\/j.beha.2019.101139_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428199909058492","article-title":"Thrombocytosis with Sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome","volume":"34","author":"Gupta","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10.1016\/j.beha.2019.101139_bib12","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2019.101139_bib13","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2019.101139_bib14","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Chronic myeloid disorders working group of the international cancer genome consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2019.101139_bib15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2012-09-399725","article-title":"Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms","volume":"121","author":"Cazzola","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101139_bib16","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","first-page":"93","article-title":"Myelodysplastic\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","author":"Orazi","year":"2017"},{"key":"10.1016\/j.beha.2019.101139_bib17","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","first-page":"153","article-title":"Therapy-related myeloid neoplasms","author":"Vardiman","year":"2017"},{"issue":"1","key":"10.1016\/j.beha.2019.101139_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ajh.24939","article-title":"Therapy related-chronic myelomonocytic leukemia (CMML): molecular, cytogenetic, and clinical distinctions from de novo CMML","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"year":"2017","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","author":"Swerdlow","key":"10.1016\/j.beha.2019.101139_bib19"},{"issue":"4","key":"10.1016\/j.beha.2019.101139_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2559.2012.04259.x","article-title":"CD34+ megakaryocytes (\u226530%) are associated with megaloblastic anaemia and non-acute myeloid neoplasia","volume":"61","author":"Insuasti-Beltran","year":"2012","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.beha.2019.101139_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1309\/AJCP8M4QQTAZPGRP","article-title":"E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms","volume":"141","author":"Ohgami","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.beha.2019.101139_bib22","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.101139_bib23","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","first-page":"82","article-title":"Chronic myelomonocytic leukaemia","author":"Orazi","year":"2017"},{"issue":"6","key":"10.1016\/j.beha.2019.101139_bib24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.beha.2019.101139_bib25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2019.101139_bib26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"issue":"15","key":"10.1016\/j.beha.2019.101139_bib27","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2019.101139_bib28","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2019.101139_bib29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23702","article-title":"Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia","volume":"89","author":"Cervera","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2019.101139_bib30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41379-019-0215-y","article-title":"Update on the pathologic diagnosis of chronic myelomonocytic leukemia","volume":"32","author":"Arber","year":"2019","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.beha.2019.101139_bib31","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions","volume":"104","author":"Valent","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/modpathol.2017.45","article-title":"Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.beha.2019.101139_bib33","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/modpathol.3800707","article-title":"Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology","volume":"19","author":"Orazi","year":"2006","journal-title":"Mod Pathol"},{"issue":"61","key":"10.1016\/j.beha.2019.101139_bib34","doi-asserted-by":"crossref","first-page":"103274","DOI":"10.18632\/oncotarget.21870","article-title":"Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression","volume":"8","author":"Petrova-Drus","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.beha.2019.101139_bib35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00277-018-3289-6","article-title":"Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia","volume":"97","author":"Khan","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.beha.2019.101139_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000048186","article-title":"Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis","volume":"127","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"10.1016\/j.beha.2019.101139_bib37","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41375-018-0121-1","article-title":"A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2019.101139_bib38","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3324\/haematol.11118","article-title":"A simple method for detection of major phenotypic abnormalities in myelodysplastic syndromes: expression of CD56 in CMML","volume":"92","author":"Lacronique-Gazaille","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2019.101139_bib39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/10428194.2010.533801","article-title":"Acute monoblastic\/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells","volume":"52","author":"Kern","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.beha.2019.101139_bib40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ejh.12477","article-title":"Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response","volume":"95","author":"Shen","year":"2015","journal-title":"Eur J Haematol"},{"issue":"23","key":"10.1016\/j.beha.2019.101139_bib41","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib42","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2019.101139_bib43","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2019.101139_bib44","first-page":"587","article-title":"Atypical chronic myeloid leukemias","volume":"45","author":"Oscier","year":"1997","journal-title":"Pathol Biol (Paris)"},{"issue":"11","key":"10.1016\/j.beha.2019.101139_bib45","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.101139_bib46","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","first-page":"87","article-title":"Atypical chronic myeloid leukaemia","author":"Orazi","year":"2017"},{"issue":"5","key":"10.1016\/j.beha.2019.101139_bib47","first-page":"635","article-title":"The syndrome of abnormal chromatin clumping in leukocytes","volume":"82","author":"Carulli","year":"1997","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.beha.2019.101139_bib48","first-page":"532","article-title":"The syndrome of abnormal chromatin clumping in leucocytes: clinical and biological study of a case","volume":"75","author":"Invernizzi","year":"1990","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.beha.2019.101139_bib49","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib51","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2019.101139_bib52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2014-06-579466","article-title":"Recurrent ETNK1 mutations in atypical chronic myeloid leukemia","volume":"125","author":"Gambacorti-Passerini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101139_bib53","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","first-page":"89","article-title":"Juvenile myelomonocytic leukaemia","author":"Baumann","year":"2017"},{"issue":"10","key":"10.1016\/j.beha.2019.101139_bib54","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who's the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2019.101139_bib55","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","article-title":"Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis","volume":"97","author":"Broseus","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib56","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"MPN and MPNr-EuroNet (COST Action BM0902). Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.beha.2019.101139_bib57","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Malcovati","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2019.101139_bib58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.101139_bib59","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (revised","first-page":"89","article-title":"Myelodysplastic\/myeloproliferative neoplasm, unclassifiable","author":"Orazi","year":"2017"},{"issue":"3","key":"10.1016\/j.beha.2019.101139_bib60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12185-014-1670-3","article-title":"Molecular pathogenesis of atypical CML, CMML and MDS\/MPN-unclassifiable","volume":"101","author":"Zoi","year":"2015","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2019.101139_bib61","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41375-018-0121-1","article-title":"A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone","volume":"32","author":"Patnaik","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2019.101139_bib62","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1002\/cncr.26537","article-title":"Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic\/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53","volume":"118","author":"Kanagal-Shamanna","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2019.101139_bib63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2141.1999.01537.x","article-title":"Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder\/myelodysplastic syndrome with an aggressive clinical course","volume":"106","author":"McClure","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.101139_bib64","article-title":"Myeloid neoplasms with isolated del(5q) and JAK2 V617F mutation: a grey zone combination of myelodysplastic and myeloproliferative features?","author":"Sangiorgio","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.beha.2019.101139_bib65","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/sj.leu.2404215","article-title":"The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow","volume":"20","author":"Ingram","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2019.101139_bib66","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/leu.2010.105","article-title":"WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations","volume":"24","author":"Patnaik","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib67","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2017.166173","article-title":"Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes","volume":"102","author":"Meggendorfer","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.101139_bib68","first-page":"1043","article-title":"Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy","volume":"7","author":"Musto","year":"2014","journal-title":"OncoTargets Ther"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib69","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/jcp.2009.065904","article-title":"JAK2 V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia","volume":"62","author":"Pich","year":"2009","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.1016\/j.beha.2019.101139_bib70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","article-title":"Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations","volume":"42","author":"Gur","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.beha.2019.101139_bib71","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.beha.2019.101139_bib72","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2019.101139_bib73","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692619301331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:06:50Z","timestamp":1761498410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692619301331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1521692619301331"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.101139","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelodysplastic\/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.101139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101139"}}